Human parainfluenza viruses: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 23: | Line 23: | ||
[[Human parainfluenza viruses medical therapy|Medical Therapy]] | [[Human parainfluenza viruses prevention|Prevention]] | [[Human parainfluenza viruses cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Human parainfluenza viruses future or investigational therapies|Future or Investigational Therapies]] | [[Human parainfluenza viruses medical therapy|Medical Therapy]] | [[Human parainfluenza viruses prevention|Prevention]] | [[Human parainfluenza viruses cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Human parainfluenza viruses future or investigational therapies|Future or Investigational Therapies]] | ||
==Case Studies== | |||
[[Human parainfluenza viruses case #1|Case #1]] | |||
[[Category:Pulmonology]] | [[Category:Pulmonology]] |
Revision as of 19:37, 26 September 2012
Human parainfluenza viruses Microchapters |
Differentiating Human parainfluenza viruses from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Human parainfluenza viruses On the Web |
American Roentgen Ray Society Images of Human parainfluenza viruses |
Directions to Hospitals Treating Human parainfluenza viruses |
Risk calculators and risk factors for Human parainfluenza viruses |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Human parainfluenza viruses from other Disorders
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Chest X Ray | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Case Studies